Long-term results of cardiac contractility modulation in patients with chronic heart failure
Open Access
- 28 March 2022
- journal article
- research article
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 29 (1) , 17-23
Abstract
Aim. Evaluate the overall effectiveness of cardiac contractility modulation (CCM) therapy in patients with chronic heart failure of various etiology.Methods. The study included 61 patients with chronic heart failure (NYHA class II-III), ejection fraction 20-40% and narrow QRS 1 in 29 (53.7%) patients (р=0.015), increased 6-min walk test from 265 to 343 m (р=0.029), and the MHFLQ improved from 46.1 to 35.8 (р=0.042). Non-ischemic cardiomyopathy was associated with significant improvement in MHFLQ (from 42.7 to 30.3, р=0.029) and lowering the heart failure NYHA class>1 (83.3%, vs 47.2%, p=0.012) compared to ischemic group. Conclusion. CCM is safe and effective in patients with chronic heart failure NYHA class II-III, ejection fraction 20- 40% and narrow QRS˂130 ms, who were implanted the CCM devices. Depending on the etiology of heart failure, ischemic cardiomyopathy prevailed (41 patients). All patients were performed echocardiography, 6-min walk test and Minnesota Living with Heart Failure questionnaire (MHFLQ).Results. The observation period was 25 months. All 54 patients significantly improved left ventricular ejection fraction from 32.2% to 37.6% (р=0.026) and volume parameters (left ventricle end systolic volume from 150 to 137 ml (р=0.034), left ventricle end diastolic volume from 220 to 201 ml (р=0.044), reduced the heart failure NYHA class >1 in 29 (53.7%) patients (р=0.015), increased 6-min walk test from 265 to 343 m (р=0.029), and the MHFLQ improved from 46.1 to 35.8 (р=0.042). Non-ischemic cardiomyopathy was associated with significant improvement in MHFLQ (from 42.7 to 30.3, р=0.029) and lowering the heart failure NYHA class>1 (83.3%, vs 47.2%, p=0.012) compared to ischemic group.Conclusion. CCM is safe and effective in patients with chronic heart failure NYHA class II-III, ejection fraction 20- 40% and narrow QRS˂130 ms. Non-ischemic etiology of cardiomyopathy was associated with significant improvement in MHFLQ and lowering the heart failure class.Keywords
This publication has 12 references indexed in Scilit:
- Dynamics of heart failure markers and cardiac reverse remodeling in patients receiving cardiac contractility modulation therapyRussian Journal of Cardiology, 2021
- A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility ModulationJACC: Heart Failure, 2018
- Cardiac contractility modulation therapy: Are there superresponders?HeartRhythm Case Reports, 2017
- Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case–control studyInternational Journal of Cardiology, 2016
- Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: An individual patient's data meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2014
- A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAmerican Heart Journal, 2011
- First Human Chronic Experience with Cardiac Contractility Modulation by Nonexcitatory Electrical Currents for Treating Systolic Heart Failure:Journal of Cardiovascular Electrophysiology, 2004
- ?Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failureEuropean Heart Journal, 2004
- Electrical Modulation of Cardiac Contractility: Clinical Aspects in Congestive Heart FailureHeart Failure Reviews, 2001
- Electric Currents Applied During the Refractory Period Can Modulate Cardiac Contractility In Vitro and In VivoHeart Failure Reviews, 2001